AxoSim empowers advancements in human neuroscience and accelerates the drug development process through our drug discovery platforms, NerveSim™ and BrainSim™
Learn More
Our technology enables researchers to predict human outcomes in the lab. We deliver accurate preclinical testing to help develop safer, more effective drugs.
Almost 90% of drugs that look promising in animal models fail when tested in humans, driving up the average cost and time of new drug development to $2.6 billion and 10 years or more. We deliver predictive human data in just weeks and at a fraction of the cost of in vivo studies.
Achieve the predictive readouts critical to your R&D success. We deliver clinically-relevant functional and structural metrics to improve success rates.
AxoSim's NerveSim™ Platform, powered by Nerve-on-a-Chip® facilitates prediction of both clinical neurotoxicity and efficacy in human neurodegenerative disease models earlier in the drug development pipeline.
BrainSim™ is a high quality 3D miniature brain organoid designed to serve as a human-relevant model in preclinical drug discovery.
BENSON CAPITAL PARTNERS ANNOUNCES FIRST INVESTMENT IN AXOSIM, INC. AxoSim, Inc, Provider of BrainSim™ and NerveSim™ Neurological Drug Discovery Platforms Teams with […]
Read MoreOctober 30, 2020 –Two grants from the DoD Congressionally Directed Medical Research Program and the National Institutes of Health awarded to AxoSim– […]
Read MoreAxoSim Scientist, Wesley Anderson, will be a Rapid Fire speaker at the 2020 AAPS PharmSci 360 Conference on Tuesday, November 3rd at […]
Read MoreOn Wednesday, September 30th, AxoSim Lead Scientist, Anup Sharma, PhD, spoke at our interactive webinar: Human Schwann Cells: Importance for Peripheral Neuropathy […]
Read More
